Vocal Cord Responses During Hyperventilation in Normal Individuals and in Mild and Severe Asthmatics.

NCT ID: NCT05565430

Last Updated: 2025-05-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

24 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-01

Study Completion Date

2025-02-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Investigators aim to:

1. Study the effect of hyperventilation on the development of paradoxical vocal cord movement (PVCM) in healthy individuals and in patients with mild and severe asthma,
2. Relate PVCM to airway symptoms and measurements of intra- and extra-thoracic airway hyperresponsiveness (ET-AHR),
3. Evaluate the effects of inhaled anti-cholinergic agents on PVCM induced by hyperventilation.

Hypotheses:

1. In health PVCM will not occur in response to hyperventilation,
2. In asthma PVCM will occur in response to hyperventilation,
3. Airway symptoms and ET-AHR will develop in parallel with PVCM,
4. Inhaled anticholinergic agents will prevent PVCM induced by hyperventilation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Specific aims:

Project 1 - 'Acute' hyperventilation in normal subjects and asthmatics.

Aim 1.1: To measure PVCM by endoscopy in response to a single period of hyperventilation in normal subjects and asthmatics.

Aim 1.2: To relate PVCM to symptoms in both groups. Aim 1.3: To relate PVCM to bronchial and ET-AHR before and after acute hyperventilation.

Project 2 - 'Chronic' hyperventilation and the effect on vocal cord movements in asthmatic subjects.

Aim 2.1: To measure PVCM by endoscopy in response to multiple periods of hyperventilation (twice daily over 2 weeks) in normal subjects and asthmatics.

Aim2.2: To relate PVCM to symptoms in both groups. Aim 2.1: To relate PVCM to bronchial and ET-AHR before and after chronic hyperventilation.

Project 3 (a) - Effects of anticholinergic medication on PVCM.

Aim 3.1: Determine the effect of anti-cholinergic inhaled medications on PVCM induced by hyperventilation.

Project 3 (b) - PVCM during exercise and the effects of anticholinergic medication on PVCM If no PVCM is detected in project 1 and 2, as an alternative strategy the Investigators will examine PVCM that has been shown to occur in severe asthma in response to exercise. The effect of anti-cholinergic inhaled medications will then be examined in this model.

Significance:

Dysfunctional breathing may be a mechanism whereby symptomatic PVCM develops in asthma but not in health. The proposed studies will enhance the Investigators understanding of the role played by dysfunctional breathing in the pathogenesis of this distressing condition and may provide a rationale for targeted therapies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperventilation Larynx Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Control

1. Acute Hyperventilation and effects on vocal cord movement.
2. Chronic Hyperventilation and effects on vocal cord movement.
3. Effects of anticholinergic medication on paradoxical vocal cord movement.

Acute Hyperventilation

Intervention Type OTHER

Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.

Chronic hyperventilation

Intervention Type OTHER

Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.

Effects of anticholinergic medication

Intervention Type DRUG

Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.

Mild Asthmatics

1. Acute Hyperventilation and effects on vocal cord movement.
2. Chronic Hyperventilation and effects on vocal cord movement.
3. Effects of anticholinergic medication on paradoxical vocal cord movement.

Acute Hyperventilation

Intervention Type OTHER

Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.

Chronic hyperventilation

Intervention Type OTHER

Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.

Effects of anticholinergic medication

Intervention Type DRUG

Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.

Severe Asthmatics

1. Acute Hyperventilation and effects on vocal cord movement.
2. Chronic Hyperventilation and effects on vocal cord movement.
3. Effects of anticholinergic medication on paradoxical vocal cord movement.

Acute Hyperventilation

Intervention Type OTHER

Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.

Chronic hyperventilation

Intervention Type OTHER

Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.

Effects of anticholinergic medication

Intervention Type DRUG

Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acute Hyperventilation

Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.

Intervention Type OTHER

Chronic hyperventilation

Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.

Intervention Type OTHER

Effects of anticholinergic medication

Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Acute Hyperventilation in normal subjects and asthmatics Effects of anticholinergic medication on vocal cord movement

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \>18 to 65 years old
* non-smokers
* No history of chronic respiratory symptoms.


* The Investigators shall recruit a total of 16 patients with asthma - 8 patients with mild asthma (Group 2) and 8 patients with severe asthma (Group 3).

* Mild asthma will be defined as patients with forced expiratory volume in 1 second (FEV1) \>80% predicted.
* Severe asthma will be defined as patients with FEV1 50-60% predicted.
* Asthmatics will also have a forced expiratory ratio (FER) less than the lower limit of normal, indicating obstruction.

* age 18-65 years
* A history of asthma defined as a bronchodilator response with increase in FEV1 \>12% and 200mls or positive bronchoprovocation testing (methacholine).
* Asthmatics will have FEV1 \>50% predicted.

Exclusion Criteria

* Age \< 18 or \> 65, smokers or smoking history \>10 pack years
* Any history of respiratory disorders such as asthma or chronic obstructive pulmonary disease (COPD)
* Known vocal cord pathology (i.e. laryngeal cancer) or diagnosed voice condition
* Known brain or brainstem cancer
* Known head and neck cancer
* Known neurological disorders (i.e. stroke)
* Use of medications (i.e. beta-blockers or anti-cholinergic agents which may interfere with vocal cord function)
* Singers
* Pregnancy.



* Age \< 18 or \> 65
* Smoking history \> 10 pack years,
* FEV1 \< 50% predicted
* Allergy to anti-cholinergics, known COPD
* Known vocal cord pathology (i.e. laryngeal cancer) or diagnosed voice condition
* Known brain or brainstem cancer
* Known head and neck cancer
* Known neurological disorders (i.e. stroke)
* Singers
* Pregnancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Monash Medical Centre

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Laurence Ruane

Respiratory Scientist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Laurence Ruane, BSc

Role: PRINCIPAL_INVESTIGATOR

Monash Health and Monash University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Monash Medical Centre

Clayton, Victoria, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

16151A

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.